5 ways to like a Pfizer-AZ merger
This article was originally published in Scrip
Executive Summary
There's been a lot of ink spilled on why Pfizer buying AstraZeneca would be a terrible idea. It would strike a body blow to UK science. It would cost people their jobs at both firms. It would deprive US national coffers of their rightful tax revenues. It would deflect attention from the business at hand just when focusing on R&D is critically urgent. The combined group would simply be an even huger entity facing declining sales (two wrongs don't make a right).